CL2024000992A1 - Métodos y productos para tratar sujetos con trastornos del espectro autista - Google Patents

Métodos y productos para tratar sujetos con trastornos del espectro autista

Info

Publication number
CL2024000992A1
CL2024000992A1 CL2024000992A CL2024000992A CL2024000992A1 CL 2024000992 A1 CL2024000992 A1 CL 2024000992A1 CL 2024000992 A CL2024000992 A CL 2024000992A CL 2024000992 A CL2024000992 A CL 2024000992A CL 2024000992 A1 CL2024000992 A1 CL 2024000992A1
Authority
CL
Chile
Prior art keywords
salt
ticagrelor
disorder
products
methods
Prior art date
Application number
CL2024000992A
Other languages
English (en)
Spanish (es)
Inventor
Zisapel Nava
Laudon Moshe
Original Assignee
Neurim Pharmaceuticals 1991 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals 1991 Ltd filed Critical Neurim Pharmaceuticals 1991 Ltd
Publication of CL2024000992A1 publication Critical patent/CL2024000992A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2024000992A 2021-10-04 2024-04-03 Métodos y productos para tratar sujetos con trastornos del espectro autista CL2024000992A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163251935P 2021-10-04 2021-10-04

Publications (1)

Publication Number Publication Date
CL2024000992A1 true CL2024000992A1 (es) 2024-09-13

Family

ID=83688729

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024000992A CL2024000992A1 (es) 2021-10-04 2024-04-03 Métodos y productos para tratar sujetos con trastornos del espectro autista

Country Status (16)

Country Link
US (1) US11878016B2 (cg-RX-API-DMAC10.html)
EP (1) EP4412616A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024536341A (cg-RX-API-DMAC10.html)
KR (1) KR20240089377A (cg-RX-API-DMAC10.html)
CN (1) CN118265521A (cg-RX-API-DMAC10.html)
AU (2) AU2022358998B2 (cg-RX-API-DMAC10.html)
CA (1) CA3232273A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024000992A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024005762A2 (cg-RX-API-DMAC10.html)
CR (1) CR20240184A (cg-RX-API-DMAC10.html)
EC (1) ECSP24033949A (cg-RX-API-DMAC10.html)
IL (1) IL311681B2 (cg-RX-API-DMAC10.html)
MX (1) MX2024004150A (cg-RX-API-DMAC10.html)
PE (1) PE20241338A1 (cg-RX-API-DMAC10.html)
TW (1) TW202322821A (cg-RX-API-DMAC10.html)
WO (1) WO2023057879A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025051399A1 (en) * 2023-09-10 2025-03-13 Dafechem Ltd Liquid ticagrelor formulation
WO2025247961A1 (en) * 2024-05-31 2025-12-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Lpa-lpar signaling as a therapeutic target or diagnostic tool for brain diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9233966B2 (en) * 2012-04-05 2016-01-12 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
CN104971042B (zh) 2014-04-04 2018-01-05 中国医学科学院医药生物技术研究所 替格瑞洛口服自微乳组合物
CN104434931A (zh) * 2014-11-06 2015-03-25 南京华威医药科技开发有限公司 含替格瑞洛和阿司匹林的复方口服固体剂及其制备方法
CN105669674A (zh) * 2014-11-21 2016-06-15 重庆圣华曦药业股份有限公司 一种替卡格雷新晶型及其在药物制剂中的应用
RS66536B1 (sr) * 2016-04-21 2025-03-31 Astrazeneca Ab Tablete za oralno raspadanje
CN105943515A (zh) * 2016-06-24 2016-09-21 山东鲁抗医药股份有限公司 一种替格瑞洛口腔崩解片及其制备方法
CN108078944A (zh) * 2016-11-22 2018-05-29 重庆植恩药业有限公司 含有替格瑞洛的固体组合物及其制备方法
TR201617983A2 (tr) * 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Ti̇cagrelorun kati oral farmasöti̇k bi̇leşi̇mleri̇
US10614684B2 (en) * 2017-01-31 2020-04-07 The United States Government As Represented By The Treatment of kidney diseases associated with elevated AVP
EP3700525A4 (en) * 2017-10-27 2021-08-25 Beyond Barriers Therapeutics, Inc. IMPROVED PROVISION OF ANTIOXIDANTS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES WITH OXIDATIVE STRESS
KR102007731B1 (ko) * 2018-02-12 2019-08-06 충남대학교산학협력단 티카그렐러를 포함하는 자가 미세유화 약물전달시스템 조성물 및 이의 제조방법
CN110876750A (zh) * 2018-09-06 2020-03-13 江苏恒瑞医药股份有限公司 一种含有替格瑞洛或其可药用盐的缓释组合物
CA3179635A1 (en) * 2020-05-29 2021-12-02 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane

Also Published As

Publication number Publication date
IL311681B1 (en) 2025-10-01
KR20240089377A (ko) 2024-06-20
IL311681B2 (en) 2026-02-01
CR20240184A (es) 2024-07-03
MX2024004150A (es) 2024-04-22
EP4412616A1 (en) 2024-08-14
TW202322821A (zh) 2023-06-16
CO2024005762A2 (es) 2024-05-30
US20230105540A1 (en) 2023-04-06
CA3232273A1 (en) 2023-04-13
US11878016B2 (en) 2024-01-23
JP2024536341A (ja) 2024-10-04
CN118265521A (zh) 2024-06-28
PE20241338A1 (es) 2024-07-03
AU2022358998B2 (en) 2025-09-11
AU2025242229A1 (en) 2025-10-23
AU2022358998A1 (en) 2024-04-11
IL311681A (en) 2024-05-01
WO2023057879A1 (en) 2023-04-13
ECSP24033949A (es) 2024-06-28

Similar Documents

Publication Publication Date Title
ECSP24033949A (es) Métodos y productos para tratar sujetos con trastornos del espectro autista
Wang et al. The effects of microglia-associated neuroinflammation on Alzheimer’s disease
Ohashi et al. Role of inflammatory processes in hemorrhagic stroke
Foreman The pathophysiology of delayed cerebral ischemia
Hroudová et al. Mitochondrial dysfunctions in neurodegenerative diseases: relevance to Alzheimer’s disease
Peng et al. Rosiglitazone polarizes microglia and protects against pilocarpine‐induced status epilepticus
Prager et al. Seizure‐induced microvascular injury is associated with impaired neurovascular coupling and blood–brain barrier dysfunction
Busche et al. Impairments of neural circuit function in Alzheimer's disease
Eren et al. The NLRP3 inflammasome: a new player in neurological diseases
Laskowski et al. Pathophysiology of mild TBI: implications for altered signaling pathways
Zhang et al. The clinical correlation between Alzheimer's disease and epilepsy
Ryu et al. Critical role of calpain in axonal damage‐induced retinal ganglion cell death
Vilela et al. Cannabidiol rescues acute hepatic toxicity and seizure induced by cocaine
Andrade-Talavera et al. Synaptic plasticity and oscillations in Alzheimer’s disease: a complex picture of a multifaceted disease
Hagelauer et al. In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes
RU2014139834A (ru) Способ улучшения функциональной синаптической связи
Gao et al. Glial cells: an important switch for the vascular function of the central nervous system
MX363322B (es) Metodos, aparatos y sistemas para el diagnostico y tratamiento de trastornos del estado de animo.
Ono et al. Pharmacological potential of cilostazol for Alzheimer’s disease
Singh et al. Agmatine for combined treatment of epilepsy, depression and cognitive impairment in chronic epileptic animals
Bojja et al. What is the Role of Lithium in Epilepsy?
PE20211065A1 (es) Metodo para tratar la epilepsia
Lima et al. Mesenchymal stromal cells protect against vascular damage and depression-like behavior in mice surviving cerebral malaria
Davies et al. Sphingolipids in neuroinflammation
Suresh et al. Modulation of microglia activation and Alzheimer's disease: CX3 chemokine ligand 1/CX3CR and P2X7R signaling